ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 838

Association of Urinary and Serum Soluble Fn14 Levels and TWEAK Levels with Lupus Nephritis Disease Activity

Irene Blanco1, Ping Wu2, Timothy S. Zheng3, Shawn Weng4, Jennifer S. Michaelson2, Linda C. Burkly2 and Chaim Putterman5, 1Rheumatology, Albert Einstein College of Medicine, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3R&D - Rheumatology/Immunology, Biogen Idec Inc, Cambridge, MA, 4Biogen Idec, Inc., Cambridge, MA, 5Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We have showed that the cytokine TWEAK is a biomarker for lupus nephritis (LN). However, soluble receptors for key immune pathways are also potential biomarkers of inflammatory diseases, including SLE. Thus, we hypothesized that a soluble form of TWEAK receptor, Fn14, might be present in human serum or urine and could be a biomarker for LN.

Methods:

Serum and urine from 67 patients from the Einstein Lupus Cohort were included in this study. 34 had active LN (renal SLEDAI≥4) and 33 had inactive, non-LN SLE (general SLEDAI≤2). Healthy normals (n=39), age and race matched, were also evaluated. ELISAs were performed on serum and urine samples to determine soluble Fn14 and TWEAK levels.  All data was analyzed using STATA 10.1

Results:

Of the 106 patients, 47% were Black, 47% were Hispanic and 6% were of another race/ethnicity. 79% were female with a median age of 43y. For the SLE patients the median disease duration was 6.0y. As expected LN patients had higher median protein to creatinine ratios as compared to both inactive SLE patients and normals (1.22 v 0.11 v 0.09, p<0.001).  Although the normal group had a higher median GFRs overall, all groups had normal median values (90 v 89 v 115, p=0.02)

Serum Fn14 (sFn14) levels were significantly higher in LN compared to normals (p=0.002) and trended toward significance when comparing LN to the inactive SLE group (p=0.06). Median urine Fn14 levels tended to be higher in the LN group as compared the inactive SLE (p=0.06) and normals (p=0.05) but did not achieve significance with normalization to urine creatinine (p=0.06 and 0.12 for comparison to inactive SLE and normal, respectively). While there was no significant difference between the groups with regard to serum TWEAK, as previously shown, median urinary TWEAK levels were significantly elevated in the LN group compared to inactive SLE and normal groups when normalized to urine creatinine concentration (LN v inactive SLE (p=0.002) and LN v normal (p=0.002).

We performed an ROC analysis to determine the capability of sFn14 to distinguish between LN and inactive SLE as well as LN and normals. The AUC for sFn14 by itself was fair (LN v inactive SLE, AUC: 0.63; LN v normals, AUC: 0.70) while that of normalized uTWEAK was good (LN v inactive SLE, AUC: 0.77; LN v normals, AUC: 0.72). However, when the AUC for sFn14 and uTWEAK were combined the AUC was increased (LN v inactive SLE, AUC: 0.80; LN v normals, AUC: 0.76).

Conclusion:

sFn14 levels are significantly elevated in patients with LN. This novel finding contributes to our previous observations that urinary TWEAK is elevated in this patient population. Adding sFN14 levels to urinary TWEAK levels as a combined biomarker has a higher capacity than each alone to distinguish between LN and inactive SLE as well as LN and normals. sFn14 is a promising novel biomarker in LN, further underscoring the TWEAK/Fn14 pathway as a potential therapeutic target that warrants further study.

 


Disclosure:

I. Blanco,
None;

P. Wu,
None;

T. S. Zheng,

Biogen Idec,

3;

S. Weng,

BiogenIDEC,

3,

Bagen IDEC,

1;

J. S. Michaelson,

Biogen Idec,

1,

Biogen Idec,

3;

L. C. Burkly,

Biogen Idec,

1,

Biogen Idec,

3;

C. Putterman,

Biogen Idec,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-urinary-and-serum-soluble-fn14-levels-and-tweak-levels-with-lupus-nephritis-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology